Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 391

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease

Wilhelmus, Kirk R., Beck, Roy W., Moke, Pamela S., Dawson, Chandler R., Barron, Bruce A., Jones, Dan B., Kaufman, Herbert E., Kurinij, Natalie, Stulting, R. Doyle, Sugar, Joel, Cohen, Elisabeth J., Hyndiuk, Robert A., Asbell, Penny A. · 1998 · New England Journal of Medicine

Abstract

BACKGROUND: Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease. METHODS: We randomly assigned 703 immunocompetent patients who had had ocular HSV disease within the preceding year to receive 400 mg of acyclovir or placebo orally twice daily. The study outcomes were the rates of development of ocular or nonocular HSV disease during a 12-month treatment period and a 6-month observation period. RESULTS: The cumulative probability of a recurrence of any type of ocular HSV disease during the 12-month treatment period was 19 percent in the acyclovir group and 32 percent in the placebo group (P<0.001). Among the 337 patients with a history of stromal keratitis, the most common serious form of ocular HSV disease, the cumulative probability of recurrent stromal keratitis was 14 percent in the acyclovir group and 28 percent in the placebo group (P=0.005). The cumulative probability of a recurrence of nonocular (primarily orofacial) HSV disease was also lower in the acyclovir group than in the placebo group (19 percent vs. 36 percent, P<0.001). There was no rebound in the rate of HSV disease in the six months after treatment with acyclovir was stopped. CONCLUSIONS: After the resolution of ocular HSV disease, 12 months of treatment with acyclovir reduces the rate of recurrent ocular HSV disease and orofacial HSV disease. Long-term antiviral prophylaxis is most important for patients with a history of HSV stromal keratitis, since it can prevent additional episodes and potential loss of vision.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199807303390503

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 391

Metadata

Authors
Wilhelmus, K. R., Beck, R. W., Moke, P. S., Dawson, C. R., Barron, B. A., Jones, D. B., Kaufman, H. E., Kurinij, N., Stulting, R. D., Sugar, J., Cohen, E. J., Hyndiuk, R. A., & Asbell, P. A.
Venue
New England Journal of Medicine
Published
1998-07-30
Volume
339
Issue
5
Pages
300-306
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2323396504
Cited by
391
References
9
FWCI
8.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease. https://app.cochat.ai/papers/10.1056/nejm199807303390503
The paper
Wilhelmus, K. R., Beck, R. W., Moke, P. S., Dawson, C. R., Barron, B. A., Jones, D. B., Kaufman, H. E., Kurinij, N., Stulting, R. D., Sugar, J., Cohen, E. J., Hyndiuk, R. A., & Asbell, P. A. (1998). Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease. New England Journal of Medicine. https://doi.org/10.1056/nejm199807303390503

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.